Mirum Pharma director Brege sells $1.26m in shares

Mirum Pharmaceuticals (MIRM) reported robust Q2 2025 results, with revenues of $127.8 million marking a 64% year-over-year increase and significantly exceeding expectations, alongside an improved EPS of -$0.12. This led to a raised 2025 revenue guidance of $490-$510 million and subsequent positive analyst revisions, including increased price targets and reiterated Buy ratings. Concurrently, Director Laura Brege sold 17,000 shares for $1.26 million after exercising options, a transaction occurring near the stock's 52-week high following an 80% year-to-date gain and an InvestingPro assessment that the stock is trading above its fair value.

Analysis

Mirum Pharmaceuticals (MIRM) is demonstrating significant operational momentum, underscored by its second-quarter 2025 financial results. The company reported total revenues of $127.8 million, a 64% year-over-year increase that substantially beat consensus expectations of $107.36 million. This top-line strength was complemented by a narrower-than-expected loss, with an EPS of -$0.12 against a forecast of -$0.33. Management has translated this performance into heightened confidence, raising its full-year 2025 revenue guidance to a range of $490 million to $510 million, implying a 48% year-over-year growth at the midpoint. This positive outlook is echoed by the analyst community, with H.C. Wainwright and JMP Securities raising price targets to $80 and $81, respectively, and Stifel resuming coverage with a Buy rating. However, this bullish fundamental picture is tempered by valuation concerns and an insider transaction. The stock has appreciated nearly 80% year-to-date and is trading near its 52-week high, with an external analysis suggesting it may be trading above its fair value. Concurrently, a director sold 17,000 shares for $1.26 million, though it's notable this was executed after exercising options at a low $15.00 price, and the director retains a direct holding of 15,703 shares.

Key Decisions for Investors

• Given the company's strong revenue beat, improved EPS, and raised full-year guidance, investors with existing positions may consider holding to capitalize on the clear operational momentum and positive analyst sentiment.
• In light of the stock's 80% year-to-date gain and an assessment that it may be trading above fair value, it could be prudent for investors to consider trimming positions to lock in profits or implement stop-loss orders to protect gains.
• The recent insider sale, coupled with the stock trading near its 52-week high, suggests potential entrants should exercise caution and may want to wait for a more favorable entry point on a market pullback, despite the compelling growth story.